Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

R Donald HarveyPhase 1 Clinical Trials Section, Winship Cancer Institute of Emory University, Atlanta, GA, USAAbstract: Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2&n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Harvey RD
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/e61e73945e8e499f9a1d996fbc7afd8c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!